Stoke Therapeutics, Inc.(STOK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

STOK Stoke Therapeutics, Inc.

休市中 07-10 16:00:00 EDT

31.38

-1.45

-4.42%

盘后31.38

+0.000.00%

17:23 EDT

最高33.02	最低30.07	成交量61.49万
今开32.83	昨收32.83	日振幅8.99%
总市值19.54亿	流通市值14.73亿	总股本6,227万
成交额1,921万	换手率1.31%	流通股本4,695万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"STOK","market":"US","secType":"STK","nameCN":"Stoke Therapeutics, Inc.","latestPrice":31.38,"timestamp":1783713600000,"preClose":32.83,"halted":0,"volume":614856,"hourTrading":{"tag":"盘后","latestPrice":31.38,"preClose":31.38,"latestTime":"17:23 EDT","volume":56366,"amount":1768765.08,"timestamp":1783718586500,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.04416692049954308,"floatShares":46951600,"shares":62271100,"eps":-2.805166,"marketStatus":"休市中","change":-1.45,"latestTime":"07-10 16:00:00 EDT","open":32.83,"high":33.02,"low":30.07,"amount":19207050.03624,"amplitude":0.089857,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.805166,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1783929600000},"marketStatusCode":7,"adr":0,"listingDate":1560916800000,"exchange":"NASDAQ","adjPreClose":32.83,"preHourTrading":{"tag":"盘前","latestPrice":32.92,"preClose":32.83,"latestTime":"09:24 EDT","volume":558,"amount":18390.308436,"timestamp":1783689894718,"change":0.09,"changeRate":0.002741,"amplitude":0.004874},"postHourTrading":{"tag":"盘后","latestPrice":31.38,"preClose":31.38,"latestTime":"17:23 EDT","volume":56366,"amount":1768765.08,"timestamp":1783718586500,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7462851781551797,"impliedVol":1.1661,"impliedVolPercentile":0.8247},"requestUrl":"/m/hq/s/STOK","defaultTab":"news","newsList":[{"id":"1170325153","title":"Stoke Therapeutics宣布Dravet综合征在研药物Zorevunersen III期EMPEROR研究完成162名患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1170325153","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170325153?lang=zh_cn&edition=full","pubTime":"2026-07-06 15:27","pubTimestamp":1783322842,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics, Inc. 宣布，其用于治疗Dravet综合征的在研药物Zorevunersen的III期EMPEROR研究已完成患者入组工作，共计招募162名患者。该公司计划于2027年第一季度启动向美国食品药品监督管理局（FDA）滚动提交新药申请（NDA）的程序。关键的III期临床数据预计将在2027年第三季度读出，并计划在2027年下半年完成NDA的全部提交。值得注意的是，在该III期EMPEROR研究中，目前尚无患者中止治疗。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","STOK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151035407","title":"Stoke Therapeutics：关键III期数据预计2027年第三季度揭晓，新药申请拟于下半年提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1151035407","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151035407?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:03","pubTimestamp":1782821003,"startTime":"0","endTime":"0","summary":"生物技术公司 Stoke Therapeutics 近日披露了其研发管线的重要时间表。备受关注的关键性III期临床试验数据，预计将于2027年第三季度获得最终结果。紧随其后，公司计划在2027年下半年完成向监管机构提交新药上市申请（NDA）的工作。\n这一进展标志着该公司在研疗法向商业化迈出了关键一步。市场分析人士普遍关注该时间节点的数据表现，因其将直接影响该疗法的获批前景及公司未来的市场估值。投资者将密切关注后续进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","STOK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115476844","title":"斯托克治疗公司宣布Dravet综合征在研药物Zorevunersen III期EMPEROR研究完成162名患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1115476844","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115476844?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:01","pubTimestamp":1782820895,"startTime":"0","endTime":"0","summary":"斯托克治疗公司宣布，其针对Dravet综合征的在研药物Zorevunersen，其III期关键临床试验EMPEROR研究已完成全部162名患者的入组工作。这一里程碑标志着该候选疗法向潜在上市又迈进了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","STOK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189126936","title":"异动解读 | 获分析师大幅上调目标价，Stoke Therapeutics盘中大涨5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=1189126936","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189126936?lang=zh_cn&edition=full","pubTime":"2026-03-20 21:45","pubTimestamp":1774014321,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics, Inc.（STOK）今日盘中股价大涨5.39%，引起了市场的关注。消息面上，根据路透报道，华尔街券商Canaccord Genuity将Stoke Therapeutics的目标价从36美元大幅上调至60美元。分析师上调目标价通常被视为对公司未来前景的积极看法，这可能是推动股价上涨的主要原因。此次目标价上调幅度显著，反映了分析师对该公司基本面的乐观预期，从而提振了投资者的信心，并在交易时段内推动了股价的上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["STOK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177107175","title":"Stoke Therapeutics公司：前四个队列剂量递增将持续至2026年及2027年初，视安全性和耐受性评估结果而定","url":"https://stock-news.laohu8.com/highlight/detail?id=1177107175","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177107175?lang=zh_cn&edition=full","pubTime":"2026-02-11 20:32","pubTimestamp":1770813165,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics公司宣布，其研究项目的前四个队列剂量递增阶段将延续至2026年及2027年初。这一进程的推进将完全取决于对药物安全性和耐受性的持续评估结果。公司强调，只有在确保患者安全的前提下，才会逐步实施剂量提升方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STOK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107932883","title":"Stoke Therapeutics宣布首位患者接受STK-002一期临床研究给药，该药物有望成为治疗常染色体显性遗传性视神经萎缩（ADOA）的疾病修正疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1107932883","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107932883?lang=zh_cn&edition=full","pubTime":"2026-02-11 20:31","pubTimestamp":1770813074,"startTime":"0","endTime":"0","summary":"生物技术公司Stoke Therapeutics, Inc.宣布，其在研药物STK-002的一期临床研究已完成对首位患者的给药。STK-002被开发为一种潜在的疾病修正疗法，旨在治疗常染色体显性遗传性视神经萎缩（ADOA）。该阶段的研究将评估STK-002的安全性、耐受性及药代动力学特性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STOK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132037514","title":"Stoke Therapeutics公司持续探索加快Zorevunersen研发、注册及患者用药的潜在路径","url":"https://stock-news.laohu8.com/highlight/detail?id=1132037514","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132037514?lang=zh_cn&edition=full","pubTime":"2026-01-12 03:03","pubTimestamp":1768158194,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics公司正积极研究加速其候选药物Zorevunersen从研发阶段到患者可及性的全流程优化方案。该公司致力于探索包括快速审评通道在内的多种策略，以期缩短药物上市周期，使患者能更早获得创新疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","STOK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165940697","title":"Stoke Therapeutics公布治疗Dravet综合征药物Zorevunersen三期EMPEROR研究的入组完成与数据读取时间表更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1165940697","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165940697?lang=zh_cn&edition=full","pubTime":"2026-01-12 03:01","pubTimestamp":1768158082,"startTime":"0","endTime":"0","summary":"生物制药公司Stoke Therapeutics, Inc.近日宣布，针对其治疗Dravet综合征的研究药物Zorevunersen，已对关键三期临床试验EMPEROR的研究时间表进行了重要更新。此次更新主要涉及两项核心节点：患者入组工作的预计完成时间，以及三期临床研究数据的最终读取时间。Dravet综合征是一种罕见的严重儿童期发病癫痫性脑病，Zorevunersen是该公司旨在从遗传根源上治疗该疾病的研究性疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","STOK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178835213","title":"Stoke Therapeutics公司预计2026年第二季度完成150名患者入组，三期临床数据将于2027年中期公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1178835213","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178835213?lang=zh_cn&edition=full","pubTime":"2026-01-12 03:01","pubTimestamp":1768158077,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics公司宣布，计划在2026年第二季度完成150名患者的入组工作。这一关键里程碑将为后续临床研究奠定基础。公司预计，三期临床试验的数据结果将于2027年中期正式公布。这一时间表的推进，标志着公司在相关治疗领域的研发工作取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STOK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512481552","title":"Stoke Therapeutics, Inc.盘中异动 股价大跌5.05%报9.22美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512481552","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512481552?lang=zh_cn&edition=full","pubTime":"2025-02-19 23:49","pubTimestamp":1739980170,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日23时49分，Stoke Therapeutics, Inc.股票出现波动，股价大幅跳水5.05%。截至发稿，该股报9.22美元/股，成交量25.0385万股，换手率0.47%，振幅6.75%。Stoke Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.63%。Stoke Therapeutics, Inc.公司简介：Stoke Therapeutics Inc 致力于通过使用基于 RNA 的药物上调蛋白质表达来解决严重疾病的根本原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219234931abd50f55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219234931abd50f55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","STOK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512031081","title":"Chardan Capital：维持Stoke Therapeutics(STOK.US)评级，由买入调整至买入评级, 目标价由24.00美元调整至24.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512031081","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512031081?lang=zh_cn&edition=full","pubTime":"2025-02-19 19:41","pubTimestamp":1739965272,"startTime":"0","endTime":"0","summary":"Chardan Capital：维持Stoke Therapeutics(STOK.US)评级，由买入调整至买入评级, 目标价由24.00美元调整至24.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19194148264816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","STOK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512193780","title":"HC Wainwright & Co.：维持Stoke Therapeutics(STOK.US)评级，由买入调整至买入评级, 目标价由35.00美元调整至47.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512193780","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512193780?lang=zh_cn&edition=full","pubTime":"2025-02-19 02:21","pubTimestamp":1739902892,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Stoke Therapeutics(STOK.US)评级，由买入调整至买入评级, 目标价由35.00美元调整至47.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19022148243309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","STOK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512167390","title":"Stoke Therapeutics, Inc.盘中异动 临近午盘股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512167390","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512167390?lang=zh_cn&edition=full","pubTime":"2025-02-19 00:44","pubTimestamp":1739897053,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日00时44分，Stoke Therapeutics, Inc.股票出现异动，股价快速下跌5.02%。Stoke Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.56%。其相关个股中，Estrella Immunopharma Inc C/Wts 29/09/2028、Ocean Biomedical Inc C/Wts 14/02/2028 、Solid Biosciences Inc.涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃，换手率分别为404.41%、180.64%、152.15%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Abvc Biopharma, Inc.、Allogene Therapeutics, Inc.，振幅分别为148.75%、92.00%、79.17%。Stoke Therapeutics, Inc.公司简介：Stoke Therapeutics Inc 致力于通过使用基于 RNA 的药物上调蛋白质表达来解决严重疾病的根本原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219004413abd3cb9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219004413abd3cb9c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","STOK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510860954","title":"Stoke Therapeutics, Inc.盘中异动 股价大跌5.02%报10.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510860954","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510860954?lang=zh_cn&edition=full","pubTime":"2025-02-11 01:06","pubTimestamp":1739207178,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日01时06分，Stoke Therapeutics, Inc.股票出现波动，股价大幅下挫5.02%。Stoke Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.24%。其相关个股中，60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Biodexa Pharmaceuticals Plc、Dominari Holdings Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.较为活跃，换手率分别为2924.99%、1588.47%、1149.27%，振幅较大的相关个股有Immatics N V C/Wts 01/07/2025 、Abpro Holdings Inc C/Wts 12/11/2029 、Ocean Biomedical, Inc.，振幅分别为99.86%、87.80%、85.48%。Stoke Therapeutics, Inc.公司简介：Stoke Therapeutics Inc 致力于通过使用基于 RNA 的药物上调蛋白质表达来解决严重疾病的根本原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211010619a240c260&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211010619a240c260&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["STOK","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509278127","title":"Stoke Therapeutics, Inc.盘中异动 下午盘股价大跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509278127","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509278127?lang=zh_cn&edition=full","pubTime":"2025-02-08 02:24","pubTimestamp":1738952640,"startTime":"0","endTime":"0","summary":"北京时间2025年02月08日02时24分，Stoke Therapeutics, Inc.股票出现异动，股价急速下跌5.10%。Stoke Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.56%。其相关个股中，Conduit Pharmaceuticals Inc.、Sionna Therapeutics, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大，Conduit Pharmaceuticals Inc.、Tonix Pharmaceuticals Holding Corp.、Lipella Pharmaceuticals Inc.较为活跃，换手率分别为7668.46%、173.84%、123.00%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Conduit Pharmaceuticals Inc.、Tonix Pharmaceuticals Holding Corp.，振幅分别为130.43%、93.55%、53.38%。Stoke Therapeutics, Inc.公司简介：Stoke Therapeutics Inc 致力于通过使用基于 RNA 的药物上调蛋白质表达来解决严重疾病的根本原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208022401abc65c16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208022401abc65c16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","STOK","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508310463","title":"Stoke Therapeutics, Inc.盘中异动 早盘大幅上涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508310463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508310463?lang=zh_cn&edition=full","pubTime":"2025-02-04 23:06","pubTimestamp":1738681573,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日23时06分，Stoke Therapeutics, Inc.股票出现异动，股价急速上涨5.12%。Stoke Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.00%。其相关个股中，Azitra Inc、Evaxion Biotech As、Regulus Therapeutics Inc.涨幅较大，Azitra Inc、Evaxion Biotech As、Enveric Biosciences, Inc.较为活跃，换手率分别为1414.21%、852.16%、218.57%，振幅较大的相关个股有Azitra Inc、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Briacell Therapeutics Corp C/Wts 24/02/2025，振幅分别为60.25%、49.88%、40.00%。Stoke Therapeutics, Inc.公司简介：Stoke Therapeutics Inc 致力于通过使用基于 RNA 的药物上调蛋白质表达来解决严重疾病的根本原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502042306139617dd69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502042306139617dd69&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["STOK","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507672598","title":"Stoke Therapeutics, Inc.盘中异动 下午盘股价大涨5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507672598","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507672598?lang=zh_cn&edition=full","pubTime":"2025-01-31 03:12","pubTimestamp":1738264336,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日03时12分，Stoke Therapeutics, Inc.股票出现异动，股价快速上涨5.14%。Stoke Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。其相关个股中，Tectonic Therapeutic, Inc.、Alterity Therapeutics Limited、Immatics N V C/Wts 01/07/2025 涨幅较大，Kazia Therapeutics Limited、Silexion Therapeutics Corp、Alterity Therapeutics Limited较为活跃，换手率分别为1785.55%、301.33%、242.74%，振幅较大的相关个股有Cero Therapeutics Holdings, Inc.、Immatics N V C/Wts 01/07/2025 、Alterity Therapeutics Limited，振幅分别为65.98%、64.10%、61.86%。Stoke Therapeutics, Inc.公司简介：Stoke Therapeutics Inc 致力于通过使用基于 RNA 的药物上调蛋白质表达来解决严重疾病的根本原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501310312169876cfdb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501310312169876cfdb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["STOK","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505771354","title":"Stoke Therapeutics, Inc.盘中异动 急速拉升5.00%报10.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505771354","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505771354?lang=zh_cn&edition=full","pubTime":"2025-01-23 01:54","pubTimestamp":1737568489,"startTime":"0","endTime":"0","summary":"北京时间2025年01月23日01时54分，Stoke Therapeutics, Inc.股票出现波动，股价急速拉升5.00%。Stoke Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.08%。其相关个股中，Nutriband Inc C/Wts 、Immunoprecise Antibodies Ltd.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 涨幅较大，Immunoprecise Antibodies Ltd.、Hepion Pharmaceuticals, Inc.、Cardio Diagnostics Holdings Inc.较为活跃，换手率分别为977.42%、307.75%、76.95%，振幅较大的相关个股有Immunoprecise Antibodies Ltd.、Immatics N V C/Wts 01/07/2025 、Nutriband Inc C/Wts ，振幅分别为60.53%、53.51%、50.39%。Stoke Therapeutics, Inc.公司简介：Stoke Therapeutics Inc 致力于通过使用基于 RNA 的药物上调蛋白质表达来解决严重疾病的根本原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123015450960d201f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123015450960d201f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["STOK","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503916051","title":"Stoke Therapeutics, Inc.盘中异动 股价大跌5.06%报9.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503916051","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503916051?lang=zh_cn&edition=full","pubTime":"2025-01-16 23:03","pubTimestamp":1737039839,"startTime":"0","endTime":"0","summary":"北京时间2025年01月16日23时03分，Stoke Therapeutics, Inc.股票出现波动，股价大幅下挫5.06%。Stoke Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.94%。其相关个股中，Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Psyence Biomedical Ltd C/Wts 25/01/2029、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 涨幅较大，Aditxt, Inc.、Palisade Bio, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1650.68%、359.28%、232.75%，振幅较大的相关个股有Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Aditxt, Inc.、Channel Therapeutics Corporation，振幅分别为131.33%、61.60%、55.47%。Stoke Therapeutics, Inc.公司简介：Stoke Therapeutics Inc 致力于通过使用基于 RNA 的药物上调蛋白质表达来解决严重疾病的根本原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011623040098689301&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011623040098689301&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","STOK","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503635728","title":"Stoke Therapeutics, Inc.盘中异动 快速跳水5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503635728","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503635728?lang=zh_cn&edition=full","pubTime":"2025-01-15 04:40","pubTimestamp":1736887211,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日04时40分，Stoke Therapeutics, Inc.股票出现异动，股价快速下跌5.16%。Stoke Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.31%。其相关个股中，Eterna Therapeutics Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Jasper Therapeutics Inc C/Wts 24/09/2026 涨幅较大，Eterna Therapeutics Inc.、Phio Pharmaceuticals Corp.、Soligenix, Inc.较为活跃，换手率分别为1092.63%、613.28%、423.63%，振幅较大的相关个股有Eterna Therapeutics Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Matinas Biopharma Holdings, Inc.，振幅分别为170.74%、146.24%、69.81%。Stoke Therapeutics, Inc.公司简介：Stoke Therapeutics Inc 致力于通过使用基于 RNA 的药物上调蛋白质表达来解决严重疾病的根本原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115044011abaafd6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115044011abaafd6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","STOK","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.stoketherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0404},{"period":"1month","weight":0.1018},{"period":"3month","weight":-0.0859},{"period":"6month","weight":-0.0447},{"period":"1year","weight":1.6063},{"period":"ytd","weight":-0.0113}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1111},{"period":"6month","weight":0.0877},{"period":"1year","weight":0.2063},{"period":"ytd","weight":0.1071}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Stoke Therapeutics, Inc.成立于2014年6月，根据特拉华州法律注册成立。该公司是一家专注于通过RNA药物上调蛋白表达以解决严重疾病根本病因的临床后期阶段企业。凭借其专有的TANGO（靶向增强核基因输出）技术平台，公司致力于开发反义寡核苷酸药物以选择性恢复蛋白质水平。其领先的在研药物zorevunersen(STK-001)是一种具有疾病修饰潜力的疗法，目前正处于治疗重症进行性遗传性癫痫——Dravet综合征的临床后期试验阶段。公司重点关注单倍剂量不足相关疾病以及中枢神经系统和眼科疾病，其技术理念已在多个生物系统中得到概念验证。在拥有人类遗传学、RNA调控及罕见病药物开发领域丰富经验的管理团队带领下，公司持续推进其创新疗法管线。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.03437},{"month":2,"riseRate":0.428571,"avgChangeRate":0.03862},{"month":3,"riseRate":0.285714,"avgChangeRate":0.010836},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.029601},{"month":5,"riseRate":0.571429,"avgChangeRate":0.127033},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.011064},{"month":7,"riseRate":0.5,"avgChangeRate":-0.038017},{"month":8,"riseRate":0.571429,"avgChangeRate":0.139168},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.103771},{"month":10,"riseRate":0.714286,"avgChangeRate":0.110002},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.025248},{"month":12,"riseRate":0.714286,"avgChangeRate":0.122564}],"exchange":"NASDAQ","name":"Stoke Therapeutics, Inc.","nameEN":"Stoke Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Stoke Therapeutics, Inc.(STOK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Stoke Therapeutics, Inc.(STOK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Stoke Therapeutics, Inc.,STOK,Stoke Therapeutics, Inc.股票,Stoke Therapeutics, Inc.股票老虎,Stoke Therapeutics, Inc.股票老虎国际,Stoke Therapeutics, Inc.行情,Stoke Therapeutics, Inc.股票行情,Stoke Therapeutics, Inc.股价,Stoke Therapeutics, Inc.股市,Stoke Therapeutics, Inc.股票价格,Stoke Therapeutics, Inc.股票交易,Stoke Therapeutics, Inc.股票购买,Stoke Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Stoke Therapeutics, Inc.(STOK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Stoke Therapeutics, Inc.(STOK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}